# A Study to Assess the Bioequivalence of Ustekinumab by Two Different Injection Devices in Healthy Participants

> **NCT04816513** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 300 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Ustekinumab

## Key facts

- **NCT ID:** NCT04816513
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-14
- **Primary completion:** 2022-01-07
- **Final completion:** 2022-01-26
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2025-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04816513

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04816513, "A Study to Assess the Bioequivalence of Ustekinumab by Two Different Injection Devices in Healthy Participants". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04816513. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*